Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

References

• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010 Mar;54(3):969–976.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, BLM DJ, Stone GG, et al. Longitudinal analysis of ESBL and carbapenemase carriage among enterobacterales and pseudomonas aeruginosa isolates collected in Europe as part of the international network for optimal resistance monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020 May 1;75(5):1165–1173.
   PubMed Web of Science ®Google Scholar
• Süzük Yıldız S, Kaşkatepe B, Şimşek H, et al. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey. Acta Microbiol Immunol Hung. 2019 Mar 1;66(1):103–112.
   PubMed Web of Science ®Google Scholar
• Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010 May;65(5):1019–1027.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al., Infectious diseases society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (esbl-e), carbapenem-resistant enterobacterales (cre), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7): e169–e183.
   PubMedGoogle Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521–547.
   PubMed Web of Science ®Google Scholar
• McGovern PC, Wible M, El-Tahtawy A, et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 20132013/05/01/;41(5):463–467.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae: importance of combination therapy. Clin Infect Dis. 2012 Oct;55(7):943–950.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015 Jul;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017 Jul;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011 Dec;17(12):1798–1803.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012 Oct;25(4):682–707.
   PubMed Web of Science ®Google Scholar
• Isler B, Özer B, Çınar G, et al. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. Eur J Clin Microbiol Infect Dis. 2022 Mar 17;41(5):841–847.
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016 Dec 15;63(12):1615–1618.
   PubMed Web of Science ®Google Scholar
• Sousa A, Perez-Rodriguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018 Nov 1;73(11):3170–3175.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019 Feb;53(2):177–184.
   PubMed Web of Science ®Google Scholar
• Dobias J, Denervaud-Tendon V, Poirel L, et al. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319–2327.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021 Feb;21(2):226–240.
   PubMed Web of Science ®Google Scholar
• Falcone M, Daikos GL, Tiseo G, et al. Clin Infect Dis. In: Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. May, 2021;72(11):1871-1878.
   Google Scholar
• Docquier JD, Calderone V, De Luca F, et al. Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol. 2009 May 29;16(5):540–547.
   PubMed Web of Science ®Google Scholar
• Poirel L, Héritier C, Tolün V, et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004 Jan;48(1):15–22.
   PubMed Web of Science ®Google Scholar
• Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother. 2012 Jul;67(7):1597–1606.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, et al. in vitro activity of imipenem against carbapenemase-positive enterobacteriaceae isolates collected by the smart global surveillance program from 2008 to 2014. J Clin Microbiol. 2017 Jun;55(6):1638–1649.
   PubMed Web of Science ®Google Scholar
• Ahn C, Butt AA, Rivera JI, et al. OXA-48-producing Enterobacteriaceae causing bacteremia, United Arab Emirates. Int J Infect Dis. 2015 Jan;30:36–37.
   PubMed Web of Science ®Google Scholar
• Balkan II, Aygun G, Aydin S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014 Sep;26:51–56.
   PubMed Web of Science ®Google Scholar
• Cuzon G, Ouanich J, Gondret R, et al. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother. 2011 May;55(5):2420–2423.
   PubMed Web of Science ®Google Scholar
• Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013 Feb;19(2):E72–9.
   PubMed Web of Science ®Google Scholar
• Carrër A, Poirel L, Eraksoy H, et al. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother. 2008;52(8):2950–2954.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Carbapenemase-producing MA. Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011 Aug;17(8):1135–1141.
   PubMed Web of Science ®Google Scholar
• Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae Carbapenemase in Enterobacteriaceae. J Clin Microbiol. 2007;45(8):2723.
   PubMed Web of Science ®Google Scholar
• Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011 Jun;55(6):3002–3004.
   PubMed Web of Science ®Google Scholar
• Mashni O, Nazer L, Le J. Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing Klebsiella pneumoniae. Ann Pharmacother. 2019 Jan;53(1):70–81.
   PubMed Web of Science ®Google Scholar
• Poirel L, Heritier C, Tolun V, et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004 Jan;48(1):15–22.
   PubMed Web of Science ®Google Scholar
• Erdem F, Abulaila A, Aktas Z, et al. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains. Antimicrob Resist Infect Control. 2020;9(1):70.
   PubMed Web of Science ®Google Scholar
• Onal U, Sipahi OR, Pullukcu H, et al. Retrospective evaluation of the patients with urinary tract infections due to carbapenemase producing Enterobacteriaceae. J Chemother. 2020 Feb;32(1):15–20.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Bradford PA, Stone GG, et al. in vitro activity of ceftazidime-avibactam and aztreonam-avibactam against oxa-48-carrying enterobacteriaceae isolated as part of the international network for optimal resistance monitoring (inform) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother. 2018;62(12):12.
   Web of Science ®Google Scholar
• Fleischmann WA, Greenwood-Quaintance KE, Patel R. In vitro activity of plazomicin compared to amikacin, gentamicin, and tobramycin against multidrug-resistant aerobic gram-negative Bacilli. Antimicrob Agents Chemother.2020;64(2):e01711-19 .
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011 Jan;66(1):48–53.
   PubMed Web of Science ®Google Scholar
• Nazik H, Öngen B, Mete B, et al. Coexistence of blaOXA-48 and aac(6’)-Ib-cr genes in Klebsiella pneumoniae isolates from Istanbul, Turkey. J Int Med Res. 2011;39(5):1932–1940.
   PubMed Web of Science ®Google Scholar
• Galani I, Anagnostoulis G, Chatzikonstantinou M, et al. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece. Clin Microbiol Infect. 2016 Oct;22(10):898–899.
   PubMed Web of Science ®Google Scholar
• Gajamer VR, Bhattacharjee A, Paul D, et al. High prevalence of carbapenemase, AmpC β-lactamase and aminoglycoside resistance genes in extended-spectrum β-lactamase-positive uropathogens from Northern India. J Glob Antimicrob Resist. 2020 Mar;20:197–203.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011 Dec;55(12):5893–5899.
   PubMed Web of Science ®Google Scholar
• van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015 Apr;70(4):1203–1211.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014 Sep;20(9):862–872.
   PubMed Web of Science ®Google Scholar
• Demirlenk YM, Gücer LS, Uçku D, et al. A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(5):761-769.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015 Dec;46(6):616–621.
   PubMed Web of Science ®Google Scholar
• McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med. 2019 Feb 21;380(8):791–793.
   PubMed Web of Science ®Google Scholar
• Galani I, Nafplioti K, Adamou P, et al. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019 Feb 15;19(1):167.
   PubMedGoogle Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019 Feb 21;380(8):729–740.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Kaye K, . Trial for the treatment of extensively drug-resistant gram-negative bacilli Accessed 27 09 2022 . https://clinicaltrials.gov/ct2/show/NCT01597973
   Google Scholar
• Rojas LJ, Salim M, Cober E, et al. Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: laboratory Detection and Impact on Mortality. Clin Infect Dis. 2017 Mar 15;64(6):711–718.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015 Dec;21(12):1106.e1–8.
   Web of Science ®Google Scholar
• Aslan AT, Kırbaş E, Sancak B, et al. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting. Int J Antimicrob Agents. 2022 Apr;59(4):106554.
   PubMed Web of Science ®Google Scholar
• Aslan AT, Akova M. The role of colistin in the era of new β-lactam/β-lactamase inhibitor combinations. antibiotics (Basel). Antibiotics (Basel, Switzerland). 2022 Feb 20;11(2). DOI:10.3390/antibiotics11020277.
   PubMed Web of Science ®Google Scholar
• Oteo J, Ortega A, Bartolomé R, et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother. 2015;59(6):3406–3412.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, BLM DJ, Stone GG, et al. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. J Antimicrob Chemother. 2018 Oct 1;73(10):2782–2788.
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis. 2019;13(7):S565–s575.
   Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010 Oct;68(2):140–151.
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7(11):1459–1470.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Cheung D, Adam H, et al. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs. 2016 Apr;76(5):567–588.
   PubMed Web of Science ®Google Scholar
• Demirci-Duarte S, Unalan-Altintop T, Gulay Z, et al. In vitro susceptibility of OXA-48, NDM, VIM and IMP enzyme- producing Klebsiella spp. and Escherichia coli to fosfomycin. J Infect Dev Ctries. 2020 Apr 30;14(4):394–397.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
   PubMed Web of Science ®Google Scholar
• Florent A, Chichmanian R-M, Cua E, et al. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82–83.
   PubMed Web of Science ®Google Scholar
• Castón JJ, Cano A, Pérez-Camacho I, et al. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study). J Antimicrob Chemother. 2022;77(5):1452–1460.
   PubMed Web of Science ®Google Scholar
• Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018 Nov 1;73(11):3170–3175.
   PubMed Web of Science ®Google Scholar
• Caston JJ, Lacort-Peralta I, Martin-Davila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017 Jun;59:118–123.
   PubMed Web of Science ®Google Scholar
• Both A, Büttner H, Huang J, et al. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2017 Sep 1;72(9):2483–2488.
   PubMed Web of Science ®Google Scholar
• Fröhlich C, Sørum V, Thomassen AM, et al. OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. mSphere. 2019; 4(2). 10.1128/mSphere.00024-19
   PubMed Web of Science ®Google Scholar
• Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother. 2013 Jul;57(7):3299–3306.
   PubMed Web of Science ®Google Scholar
• Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):4.
   Web of Science ®Google Scholar
• Avery LM, Nicolau DP. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: defining the zone of hope. Int J Antimicrob Agents. 2018 Nov;52(5):688–691.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018 Feb 1;73(2):542–544.
   PubMed Web of Science ®Google Scholar
• Pfizer. A study to determine the efficacy, safety and tolerability of aztreonam-avibactam (atm-avi) ± metronidazole (mtz) versus meropenem (mer) ± colistin (col) for the treatment of serious infections due to gram negative bacteria. Revisit. 2019 Accessed 27 09 2022; https://clinicaltrials.gov/ct2/show/NCT03329092
   Google Scholar
• Pfizer. Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria Accessed 27 09 2022. https://clinicaltrials.gov/ct2/show/NCT03580044.
   Google Scholar
• Sadek M, Juhas M, Poirel L, et al. genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-β-lactamase-producing Escherichia coli isolates. Antimicrob agents chemother. 2020;64(17):e01659-20.
   PubMedGoogle Scholar
• Ma K, Feng Y, McNally A, et al. Struggle to survive: the choir of target alteration, hydrolyzing enzyme, and plasmid expression as a novel aztreonam-avibactam resistance mechanism. In: mSystems, Vol. 5. 2020 Nov 3;5(6):e00821-20.
   Google Scholar
• Nordmann P, Yao Y, Falgenhauer L, et al. Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0109021.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clinl Infect Dis. 2019;69(7):S538–S543.
   PubMedGoogle Scholar
• Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases. Antimicrob Agents Chemother. 2019;63(1):1.
   Web of Science ®Google Scholar
• Food US, Administration D. FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance Accessed 27 09 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts.
   Google Scholar
• Food and Drug Administration (FDA). FDA Briefing Document Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). Cefiderocol Injection. October. 2019;16 page 45 doi:https://www.fda.gov/media/131703/download Accessed 27 09 2022 .
   Google Scholar
• Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC-Antimicrob Resist. 2021;3(3):92.
   Google Scholar
• Timsit JF, Paul M, Shields RK, et al. Clin Infect Dis. In: Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies. Feb, 2022. 11. DOI: 10.1093/cid/ciac078
   Google Scholar
• Falcone M, Tiseo G, Leonildi A, et al. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022 Mar;21(5):e0214221.
   Google Scholar
• Wright H, Harris PNA, Chatfield MD, et al. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials. 2021 Dec 7;22(1):889.
   PubMed Web of Science ®Google Scholar
• Lowman W, Schleicher G. Antimicrobial treatment and outcomes of critically ill patients with OXA-48 like carbapenemase-producing Enterobacteriaceae infections. Diagn Microbiol Infect Dis. 2015 Feb;81(2):138–140.
   PubMed Web of Science ®Google Scholar
• Madueño A, González-García J, Mdm AS, et al. Clinical features and outcomes of bacteraemia due to OXA-48-like carbapenemase-producing Klebsiella pneumoniae in a tertiary hospital. Enferm Infecc Microbiol Clin. 2018 Oct;36(8):498–501.
   Web of Science ®Google Scholar
• Ming DK, Otter JA, Ghani R, et al. Clinical risk stratification and antibiotic management of NDM and OXA-48 carbapenemase-producing Enterobacteriaceae bloodstream infections in the UK. J Hosp Infect. 2019 May;102(1):95–97.
   PubMed Web of Science ®Google Scholar
• Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and Bacterial Risk Factors for Mortality in Children With Carbapenem-resistant Enterobacteriaceae Bloodstream Infections in India. Pediatr Infect Dis J. 2017 Jun;36(6):e161–e166.
   PubMed Web of Science ®Google Scholar
• Alraddadi BM, Saeedi M, Qutub M, et al. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019 Sep 4;19(1):772.
   PubMed Web of Science ®Google Scholar
• De la Calle C, Rodríguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019 Apr;53(4):520–524.
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrobial Agents and Chemotherapy. 2017;61(2):e01964–16.
   PubMed Web of Science ®Google Scholar